Antaros Medical’s kidney imaging methodology study presented at the ESMRMB congress 2020
October 1st, 2020
Antaros Medical are proud partners of the Cooperation in Science and Technology (COST) action PARENCHIMA, aiming to boost the use of renal magnetic resonance imaging (MRI) biomarkers to improve the management of chronic kidney disease (CKD) patients. During the PARENCHIMA collaboration session at this year’s European Society for Magnetic Resonance in Medicine and Biology (ESMRMB) congress, Iris Friedli (Imaging Director at Antaros Medical) will present data from Antaros Medical’s kidney imaging methodology study.
MRI has great potential to non-invasively give a comprehensive assessment of several functional and morphologic, including fibrotic, changes in the kidney that may improve diagnosis, prognosis, and treatment monitoring in patients with CKD. The presented study, a collaboration between Antaros Medical, Sahlgrenska University Hospital and AstraZeneca, strengthens use of MRI as a tool for drug development in CKD.
If you want to hear more, join Iris in her presentation ‘Repeatability and Sensitivity of MRI Biomarkers of CKD, Relation to GFR and UACR’ during the Collaboration Session – Renal MRI, PARENCHIMA (1 October, 18.07) at the ESMRMB 2020.
Back to all news